Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.01 (-0.32%)

    Market Cap: $10.17M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Intensity Therapeutics, Inc. Common stock (INTS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Intensity Therapeutics, Inc. Common stock reported EPS of -$1.09, below the -$0.94 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    27%(4/15)
    Avg Surprise
    -52.97%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.77
    Range-$1.09 - -$0.21
    7 analysts
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.51
    Range-$0.81 - -$0.21
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago-$0.510.0%
    30d ago-$0.510.0%
    7d ago-$0.510.0%
    Current-$0.51
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    INTS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    INTS Earnings Call

    The latest INTS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 15 quarters below that had an estimate, INTS beat 4, missed 8 and matched 3. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 431.82% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.09-$0.94-$1.12 - -$0.77-15.96%MissN/A40 up, 3 downNov 5, 2026
    Jun 30, 2026-$1.11-$0.81-$0.93 - -$0.58-37.04%MissN/A42 up, 1 downAug 11, 2026
    Mar 31, 2026-$0.96-$1.09-$1.19 - -$1.02+11.93%BeatN/A30 up, 0 downMay 7, 2026
    Dec 31, 2025-$1.21-$1.25-$1.45 - -$1.00+3.31%BeatN/A31 up, 0 downMar 27, 2026
    Sep 30, 2025-$1.50-$1.50-$1.50 - -$1.500.00%In lineN/A20 up, 0 downNov 6, 2025
    Jun 30, 2025-$0.13-$0.16N/A+18.75%BeatN/A10 up, 0 downAug 7, 2025
    Mar 31, 2025-$5.50-$3.25-$3.25 - -$3.25-69.23%MissN/A10 up, 0 downMay 13, 2025
    Dec 31, 2024-$1.17-$0.22N/A-431.82%MissN/AN/A0 up, 0 downMar 13, 2025
    Sep 30, 2024-$6.25-$7.62-$9.25 - -$4.00+17.98%BeatN/A40 up, 2 downNov 13, 2024
    Jun 30, 2024-$9.00-$8.00-$8.50 - -$7.50-12.50%MissN/A20 up, 0 downAug 8, 2024
    Mar 31, 2024-$8.50-$8.50N/A0.00%In lineN/A10 up, 0 downMay 9, 2024
    Dec 31, 2023-$0.23-$0.18-$0.18 - -$0.18-28.56%MissN/A10 up, 0 downMar 14, 2024
    Sep 30, 2023-$4.25-$2.25-$2.25 - -$2.25-88.89%MissN/A10 up, 0 downNov 13, 2023
    Jun 30, 2023-$26.25-$10.00-$10.00 - -$10.00-162.50%MissN/A10 up, 0 downAug 14, 2023
    Mar 31, 2023-$0.39-$0.39N/A0.00%In lineN/AN/AN/AJun 30, 2023
    Sep 30, 2021-$0.24N/AN/AN/AN/AN/AN/AN/AOct 28, 2021
    Jun 30, 2021-$0.49N/AN/AN/AN/AN/AN/AN/ASep 20, 2021
    Last 17 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$8.34, after -$24.92 the year before. It was -$31.85 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$8.34N/A
    Dec 31, 2024-$24.92N/A
    Dec 31, 2023-$31.85N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,2257
    2026Q2Jun 30, 20265,4107

    2026Q3 Earnings Call

    Opening remarks

    Lewis Bender President and CEO Thank you, Wyatt, and thank you, everyone, for joining us this morning. It is my pleasure to provide the latest update of our company's progress in the INVINCIBLE-3 and INVINCIBLE-4 studies, our publications and presentation strategy, our business development activities, and our plans for the rest of 2026 into 2027. First, I will turn the call over to Joe Talamo, our CFO, to discuss our third quarter financial results. Joe?

    Joseph Talamo CFO Thanks, Lou, and good morning. I'm pleased to join you today and to present a summary of our third quarter 2026 financial results. Our research and development expenses were $2.4 million for the third quarter of 2026, compared with $1.6 million for the same prior-year period, reflecting an increase of $876,000, or 56%. Clinical trial expenses for our Phase III INVINCIBLE-3 study were $1.5 million during the third quarter of 2026, compared with $1 million for the same prior-year period. In the current-year quarter, we resumed new patient enrollment activities in the INVINCIBLE-3 study at a limited number of U.S. sites after pausing new site activations and patient enrollment in March 2025 due to funding constraints. During this pause, we continued to treat and monitor patients previously enrolled in the study in cooperation with our clinical research organizations. We have prioritized commencing full patient enrollment and site activations once sufficient incremental funding is obtained. Our clinical trial expenses also included $104,000 for our Phase II INVINCIBLE-4 study, which also resumed patient enrollment and treatment in the third quarter of 2026. We expect the INVINCIBLE-4 study costs to increase in the coming quarters as we target completing enrollment in this study by the end of 2027. Lou will provide an operational update on both studies shortly. During the third quarter of 2026, we also initiated a new manufacturing batch of INT230-6, incurring $162,000 in higher manufacturing costs. We expect this batch will be completed in the first quarter of 2027 and will likely be sufficient to fully supply both ongoing clinical studies. Lastly, research and development employee compensation-related expenses were $184,000 higher during the current quarter due to an estimated bonus accrual in the current-year period, compared with no bonus accrual in the prior-year period. Turning now to G&A. General and administrative expenses were $1.3 million for the third quarter of 2026 and were unchanged compared with the same prior-year period. Within G&A, minor increases in employee compensation-related expenses and consulting expenses were offset by minor decreases in insurance costs during the third quarter of 2026 compared with the same prior-year period.

    Frequently Asked Questions About INTS

    Did INTS beat earnings estimates last quarter?

    No. Intensity Therapeutics, Inc. Common stock reported EPS of -$1.09 for the quarter ended Sep 30, 2026, below the -$0.94 estimate by 15.96%.

    What EPS do analysts expect from INTS next quarter?

    The consensus EPS estimate for Intensity Therapeutics, Inc. Common stock for the quarter ending Dec 31, 2026 is -$0.77 from 7 analysts, with estimates from -$1.09 to -$0.21.

    How often does INTS beat earnings estimates?

    Intensity Therapeutics, Inc. Common stock beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -65.01%.